Compare Citius Pharmaceuticals Inc (CTXR) vs Western Alliance Bancorporation (WAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Western Alliance Bancorporation — how do they compare? Citius Pharmaceuticals Inc trades at $0.53 (market cap $14.64M), while Western Alliance Bancorporation trades at $80.41 (market cap $8.77B). The key difference: Western Alliance Bancorporation is far larger — about 599× Citius Pharmaceuticals Inc's market cap, and Western Alliance Bancorporation pays a 2.09% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | WAL | |
|---|---|---|
Market Cap | $14.64M | $8.77B |
Sector | Health | Financials |
52-Week High | $1.82 | $96.08 |
52-Week Low | $0.53 | $66.70 |
Enterprise Value | $10.86M | — |
Dividend Yield | — | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
Western Alliance Bancorporation (WAL) trades at $80.49, down 0.25% on the day, with a bearish technical signal and mixed fundamentals. The stock shows strong analyst support with a consensus price target of $90.67 and 79% buy ratings, but recent earnings beats are overshadowed by negative operating cash flow and high interest expenses. Recent news highlights strategic lending growth and industry recognition, including a #1 bank ranking in Arizona by Forbes in June 2026.
The outlook is cautiously optimistic given Wall Street's bullish stance and valuation discounts, but risks include cash flow pressures and macroeconomic sensitivity. Upside hinges on execution of lending growth and margin improvement, while downside could stem from credit quality deterioration or rising rates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Western Alliance Bancorporation
Western Alliance Bancorporation is a top-performing bank holding company that operates a dual business model: high-touch regional banking and specialized national business lines. It serves niche industries—including technology, life sciences, and homeowners associations—providing sophisticated commercial lending and treasury solutions that bridge the gap between regional service and national scale.
Read more on WAL →
